Detalhe da pesquisa
1.
Pharmacokinetic-Pharmacodynamic Evidence from a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
Clin Infect Dis
; 2024 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38462673